Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03001817
Study type Interventional
Source Kowa Research Institute, Inc.
Status Completed
Phase Phase 3
Start date November 28, 2016
Completion date June 24, 2019

See also
  Status Clinical Trial Phase
Completed NCT01208961 - Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation Phase 2
Recruiting NCT04541186 - Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia Phase 2
Completed NCT02189252 - An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis Phase 1
Active, not recruiting NCT01229566 - Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia Phase 3
Completed NCT03011450 - Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment Phase 3
Recruiting NCT04720534 - Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Phase 2
Not yet recruiting NCT04662528 - Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL Phase 3
Completed NCT01242527 - Epanova® for Lowering Very High Triglycerides Phase 2/Phase 3
Completed NCT02944383 - A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Phase 2
Withdrawn NCT01997268 - The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL) Phase 3